Loading
Life sciences · Journal article
Foods · September 2, 2026
Raises a question worth testing. It does not answer one.
This narrative review synthesizes preclinical evidence suggesting that ellagitannins—a class of natural tannins—may modulate pathogenic mechanisms in metabolic syndrome through effects on oxidative stress, inflammation, insulin resistance, endothelial dysfunction, and lipid metabolism. The evidence is limited to cellular and animal models; Punicalagin and Geraniin have the strongest preclinical support, while others require further validation. No human clinical efficacy data are presented.
Journal article. Metabolic syndrome and related disorders; preclinical models only—no human population studied..
Ellagitannins modulate multiple pathogenic mechanisms in metabolic syndrome: oxidative stress, chronic inflammation, insulin resistance, endothelial dysfunction, and dysregulated lipid metabolism Punicalagin and Geraniin possess the strongest preclinical evidence, supported by multiple independent studies using cellular and animal models Chebulagic acid, Corilagin, Chebulinic acid, and Punicalin show considerable promise but require further validation in diverse experimental systems
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review identifies promising natural compounds for investigation but does not provide evidence sufficient to guide clinical practice. Further human clinical trials are required before therapeutic recommendations can be made.
This is a narrative review synthesizing preclinical evidence on natural compounds; it identifies promising mechanisms and compounds but does not report clinical trials, human efficacy data, or a primary empirical result.
This review identifies promising natural compounds for investigation but does not provide evidence sufficient to guide clinical practice. Further human clinical trials are required before therapeutic recommendations can be made.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Over the years, metabolic syndrome (MetS) has emerged as one of the most significant public health challenges, driven by the global increase in obesity, physical inactivity, unhealthy dietary patterns, and population aging. Ellagitannins are a class of hydrolysable tannins that have emerged as promising natural bioactive compounds, owing to their broad spectrum of biological activities. Increasing evidence suggests that some ellagitannins and their metabolites modulate several pathogenic mechanisms underlying metabolic syndrome, including oxidative stress, chronic inflammation, insulin resistance, endothelial dysfunction, and dysregulated lipid metabolism. This work reviews the pharmacological activities and therapeutic prospects of ellagitannins in the management of metabolic syndrome-related disorders. It further provides a critical and comparative analysis of the pharmacological profiles of reported ellagitannins, offering insights into their therapeutic efficacy and potential synergistic applications in the management of MetS-related disorders. Overall, Punicalagin and Geraniin currently possess the strongest preclinical evidence, supported by multiple independent studies employing both cellular and animal models that consistently demonstrate beneficial effects across several components of MetS. Chebulagic acid, Corilagin, Chebulinic acid, and Punicalin also show considerable promise but require further validation in diverse experimental systems. Potential synergistic interactions among ellagitannins when administered in combination should be investigated for enhanced therapeutic efficacy and broader multifaceted pharmacological effects.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.